#342 Checkpoint Inhibitors: The power, and adverse effects, of immunotherapy (ACP 2022)
The Curbsiders Internal Medicine Podcast
00:00
What Are the Common Cancers?
In a substantial number of patients, across a very broad number of diseases it does better than cemo therapy in long term survival. The advances have been more in ways to manipulate the harmonal system with coalin cancer. Triple negative has been a bad actor, and that's where immunitherapies are.
Transcript
Play full episode
